Skip to content
Alfuzosin
Uroxatral (alfuzosin) is a small molecule pharmaceutical. Alfuzosin was first approved as Uroxatral on 2003-06-12. It is used to treat prostatic hyperplasia in the USA. The pharmaceutical is active against alpha-1D adrenergic receptor, alpha-1A adrenergic receptor, and alpha-1B adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
Trade Name
FDA
EMA
Uroxatral (generic drugs available since 2011-07-18)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alfuzosin hydrochloride
Tradename
Company
Number
Date
Products
UROXATRALConcordia LaboratoriesN-021287 RX2003-06-12
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
alfuzosin hydrochlorideANDA2023-01-23
uroxatralNew Drug Application2020-05-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
prostatic hyperplasiaEFO_0000284D011470N40
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04C: Drugs used in benign prostatic hypertrophy
— G04CA: Alpha-adrenoreceptor antagonists, benign prostatic hypertrophy
— G04CA01: Alfuzosin
— G04CA51: Alfuzosin and finasteride
HCPCS
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PainD010146EFO_0003843R52———235
Patient satisfactionD017060———112
NeoplasmsD009369C80———112
Pancreatic diseasesD010182K86.9———1—1
Biliary tract diseasesD001660EFO_0009534K83.9———1—1
Digestive system diseasesD004066EFO_0000405K92.9———1—1
ConfusionD003221F44.89———1—1
Emergence deliriumD000071257———1—1
Lung neoplasmsD008175C34.90———1—1
Blood pressureD001794EFO_0004325———1—1
Show 3 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Conscious sedationD016292——1——1
BronchoscopyD001999——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnesthesiaD000758————44
Drug interactionsD004347————22
Lung diseasesD008171EFO_0003818J98.4————22
Postoperative nausea and vomitingD020250EFO_0004888————11
AnalgesiaD000698————11
General anesthesiaD000768————11
HyperalgesiaD006930————11
Brain ischemiaD002545I67.82————11
AnkyloglossiaD000072676Q38.1————11
Pain measurementD010147————11
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameALFUZOSIN
INNalfuzosin
Description
Alfuzosin is a monocarboxylic acid amide, a tetrahydrofuranol and a member of quinazolines. It has a role as an antineoplastic agent, an antihypertensive agent and an alpha-adrenergic antagonist.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC
Identifiers
PDB—
CAS-ID81403-80-7
RxCUI17300
ChEMBL IDCHEMBL709
ChEBI ID51141
PubChem CID2092
DrugBankDB00346
UNII ID90347YTW5F (ChemIDplus, GSRS)
Target
Agency Approved
ADRA1D
ADRA1D
ADRA1A
ADRA1A
ADRA1B
ADRA1B
Organism
Homo sapiens
Gene name
ADRA1D
Gene synonyms
ADRA1A
NCBI Gene ID
146
Protein name
alpha-1D adrenergic receptor
Protein synonyms
adrenergic, alpha -1D-, receptor, adrenergic, alpha-1A-, receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenoceptor, Alpha-1D adrenoreceptor, Alpha-adrenergic receptor 1a
Uniprot ID
Q9NPY0
Mouse ortholog
Adra1d (11550)
alpha-1D adrenergic receptor (P97714)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,439 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
405 adverse events reported
View more details